XXII - 22nd Century Group, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.0200
-0.0100 (-0.49%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.0300
Open2.0100
Bid0.0000 x 2200
Ask0.0000 x 4000
Day's Range1.9600 - 2.0500
52 Week Range1.5800 - 3.2900
Volume630,540
Avg. Volume1,718,688
Market Cap251.813M
Beta (3Y Monthly)1.38
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents4 days ago

    Edited Transcript of XXII earnings conference call or presentation 8-May-19 8:00pm GMT

    Q1 2019 22nd Century Group Inc Earnings Call

  • 3 Marijuana Stocks to Avoid Like the Plague in May
    Motley Fool13 days ago

    3 Marijuana Stocks to Avoid Like the Plague in May

    The grass may not be greener with these particular pot stocks.

  • Associated Press13 days ago

    22nd Century: 1Q Earnings Snapshot

    The Williamsville, New York-based company said it had a loss of 2 cents per share. The plant biotechnology company posted revenue of $6.3 million in the period. The company's shares closed at $2.21. A ...

  • 7 Marijuana Stocks That Are Bleeding Cash
    InvestorPlace14 days ago

    7 Marijuana Stocks That Are Bleeding Cash

    You may find it surprising, but the Post Office, the Atlanta Hawks and these seven marijuana stocks all have something in common. At first glance, you may think they have nothing to do with each other. After all, the Post Office is run by the government, the Atlanta Hawks are a professional basketball team and cannabis companies were established to profit off of the booming legal cannabis industry.But unfortunately, these very different organizations do in fact have something in common. And it just so happens that it is a very important thing. They are all losing money! None of them have made a profit in years!Obviously, the Post Office can continue to lose money forever because it's run by the governmental and the government can just raise taxes. And a professional sports team can continue to lose money as long as the owners are willing to sustain the losses.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut let's talk about the cannabis companies In the stock market, the idea is to invest in companies that are, or will be, profitable. This profitability will, in turn, lead to the share price appreciating. Financial theory, history and common sense all tell us that if a company doesn't make money it will eventually go out of business. Investors will see declining share prices and losses.Looking at the Cannabis Companies: You are probably familiar with the following companies if you trade or invest in the cannabis markets. They may have cool products and be in a cool industry, but if you are considering investing in them, it is important to understand that they are losing money. You may ask yourself, "how have they been able to lose money for a sustained period of time?"The answer is that they borrow money or issue stock and use these proceeds to cover their expenses. But eventually, the ability to do so will stop if they are never able to turn a profit. * 7 Strong Buy Stocks That Tick All the Boxes I am not saying that these companies will never earn money and that you can't profit by investing in their stocks. Some of them may eventually become great investments. My intent here is to express my belief that before making an investment in a company, one should consider if it is actually making money and what the future prospects of profitability are. In the long run, these dynamics will ultimately have a significant effect on the share price. Axim Biotechnologies (AXIM) Click to Enlarge Axim Biotechnologies (OTCMKTS:AXIM) makes a really cool product. It is a biotechnology company based in New York City. The company makes chewing gum that is infused with medicinal cannabis. This is used to treat pain, anxiety and other conditions. It can even be used to treat opioid addiction, which we all know is a terrible epidemic. I am not really sure how they do it because I'm a stock market guy, not a scientist, but I think it sounds like an awesome idea.But let's take a look at some numbers. Last year AXIM lost 12 cents per share. That means that for the year the company lost about $6.7 million. Unfortunately, losing money is nothing new to this company. In 2017 they lost $4.2 million, in 2016 the loss was $7.3 million, and it 2015 it was just over $10 million.Not surprisingly, the stock has not acted well. It is currently trading around the $1.50 level. As you can see on the chart, over the past year it has lost about 70% of its value. Maybe someday one of the company's product will be a huge success and it will become profitable, but over the past few years, it has certainly been a disappointment to shareholders. Americann (ACAN) Click to Enlarge Americann, Inc. (OTCMKTS:ACAN) is next on the list. Like many other cannabis companies, they are based in Denver. This company develops medical cannabis cultivation and processing properties. In other words, they build greenhouses. The greenhouses they build aren't like the kind my grandfather had in his garden. These are big-time greenhouses that are used for largescale industrial growing. They have built and developed over one million square feet of growing area.Americann has been involved with some enormous projects. Some of the projects include the Denver Medical Cannabis Center, the Massachusetts Medical Cannabis Center and the Illinois Medical Cannabis Center. The company is also committed to sustainability and uses clean energy from solar and geothermal sources. * 7 Stocks to Buy From the T. Rowe Price Health Sciences Fund Apparently, the Cannabis greenhouse business isn't very profitable -- at least in the way that Americann does it. Last year they lost $4.4 million which equates to a loss of 22 cents per share. This is more than they lost in the prior few years. In 2017 the loss was $2.7 million, in 2016 it was $2.2 million, and in 2015 the loss was $1.7 million. Maybe one day the company will be profitable but, as for now, they seem to be headed in the wrong direction. General Cannabis Corp. (CANN) Click to Enlarge General Cannabis Corp. (OTCMKTS:CANN) is a holding company that is based in Denver. They have four different segments -- security, operations, consumer goods and investments.The security segment provides different types of services to cannabis growers and retails stores. These services include video surveillance, transporting cash and providing security professionals. Consulting services to the cannabis industry that include obtaining licenses, compliance, logistics, retail operations and facility services are offered by the operations segment. The consumer goods segment includes developing relationships with apparel retailers and distributors. The investments segment provides loans and financing to companies within the cannabis industry.General cannabis is clearly an organization that is involved in many things. Maybe it is involved in too many things. Have you ever heard the expression "jack of all trades and master of none?" I think that could apply here. This company hasn't earned any money in years. Last year it lost almost $17 million, or 49 cents per share. The prior year's losses were less than half of that. In 2017, the loss was just over $8 million. In 2016, General cannabis lost just over $10 million and, in 2015, the loss was almost $9 million. If you're keeping track, this company has lost a total of $44 million in the past four years. Cannabis Sativa (CBDS) Click to Enlarge Cannabis Sativa, Inc. (OTCMKTS:CBDS) is next up on the list of losers. After looking at the company website for a while, I couldn't even figure out just what they actually do. I think it has something to do with providing services to cannabis dispensaries. Here is the description from MarketWatch:"Cannabis Sativa, Inc. engages in the research, development, acquisition and licensing of specialized natural cannabis related products, including cannabis formulas, edibles, topicals, strains, recipes and delivery systems. The company was founded on November 5, 2005 and is headquartered in Mesquite, NV."This company seems very mysterious to me. According to MarketWatch, there is only one employee despite having revenues that were over $500 million. One of the things that I noticed when I was looking at the financials is that the Quick Ratio is only 0.25 while the average Quick Ratio for the industry is 2.67.The Quick Ratio is the company's cash and short-term securities divided by the current liabilities. Current typically means one year or less. In other words, Cannabis Sativa only has 25 cents for each dollar of debt that they have, while the industry average is to have $2.61 for each $1 of debt. With a ratio like that, it isn't surprising that they are losing money. * 7 Energy Stocks to Buy to Light Up Your Portfolio The losses were $4.1 million in 2018, $7.6 million in 2017, $3.1 million in 2016, and $9.4 million in 2015. Tilray (TLRY) Click to Enlarge Tilray Inc. (NASDAQ:TLRY) hasn't been a publicly traded company for that long. The initial public offering was last summer. This company has the distinction of being the first publicly traded cannabis company to list on the Nasdaq. Their business model is very understandable. They engage in research, cultivation, production, and distribution of cannabis and cannabinoids. Products include dried cannabis and cannabis extracts. In other words, they grow and sell weed.Like the others, this company is losing money as well. I have heard that the cannabis markets are glutted and that the price of cannabis has fallen dramatically since its legalization. Many cannabis farmers are losing a lot of money. Maybe that is why Tilray is losing money as well.Tilray went public last year, but they have disclosed financial information going back further. If you think about it, it is kind of amazing that a company that loses money could go public. This was a common occurrence back in the dot-com era. The company has a market capitalization of around $5 billion despite the fact that they lost $67 million last year. In 2017, they lost about $8 million and had a similar size loss in 2016. 22nd Century Group (XXII) Click to Enlarge 22nd Century Group, Inc. (OTCMKTS:XXII) is based in Clarence, New York. It is a biotech company. They research and develop technologies that will allow the increase or decrease of the levels of nicotine and nicotinic alkaloids in tobacco plants and the levels of cannabinoids in cannabis plants. My guess is that there will be greater demand for increasing than decreasing. This is done through genetic engineering and plant breeding. Sounds like pretty neat stuff.But don't let their cool name and cool stock symbol fool you. They are losing money. Last year the loss was $10.4 million. That is a loss of 8 cents per share. In 2017, the annual loss was close to $17 million. The loss in 2016 was just over $15 million and the loss in 2015 was just over $14 million. * 7 Stocks Worth Buying When They're Down Maybe this company will turn around one day and become successful, but the current shareholders must be disappointed. The valuation has fallen by about one-third since December as the price per share has fallen from $3 to $2 while the broader equity markets have been booming since then. The Supreme Cannabis Co (SPRWF) Click to Enlarge The Supreme Cannabis Co, Inc. (OTCMKTS:SPRWF) is last on the list. Obviously, there are many other cannabis companies that are losing money out there, but today I just wanted to focus on these seven because they seem to be popular recently. Supreme has a similar business model as Tilray. The company grows and sells cannabis, although the product may be a little different because they say it is '"sun-grown." I suppose this is in contrast to being grown with artificial light. Supreme does this through their wholly owned subsidiary 7ACRES.Perhaps The Supreme Cannabis Company should consider changing their name to "The Subprime Cannabis Company" because it is losing money. It has seen the price of its stock fall by about 20% since September. Last year the company lost around $7.3 million. Losses in 2017 were more than twice that at $15.3 million. The loss in 2016 was $4.4 million and the loss in 2015 was about $5.7 million. Maybe the future will be better, but my guess is that The Supreme Cannabis Company's shareholders are supremely disappointed.As of this writing, Mark Putrino did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Energy Stocks to Buy to Light Up Your Portfolio * 10 Vice Stocks to Spice Up Your Portfolio * 7 of the Best ETFs to Buy for a Slowing Economy Compare Brokers The post 7 Marijuana Stocks That Are Bleeding Cash appeared first on InvestorPlace.

  • 5 Best Pot Stocks in April -- Are They Buys Now?
    Motley Fool17 days ago

    5 Best Pot Stocks in April -- Are They Buys Now?

    These pot stocks soared last month, and two still look like great picks for investors.

  • Market Exclusive20 days ago

    22nd Century Group Announces FDA Inspection For Its Pre-Market Tobacco Application

    22nd Century Group Inc. (NYSEAMERICAN:XXII) has announced that last week the FDA carried out a comprehensive inspection of its North Carolina manufacturing facility in line with the review of the company's Pre-Market Tobacco application for its VLN cigarettes. The proposed cigarettes are produced through 22nd Century’s proprietary Very Low Nicotine Content tobacco. VLNC cigarettes have […]The post 22nd Century Group Announces FDA Inspection For Its Pre-Market Tobacco Application appeared first on Market Exclusive.

  • Investors Who Bought 22nd Century Group (NYSEMKT:XXII) Shares Three Years Ago Are Now Up 120%
    Simply Wall St.last month

    Investors Who Bought 22nd Century Group (NYSEMKT:XXII) Shares Three Years Ago Are Now Up 120%

    22nd Century Group, Inc. (NYSEMKT:XXII) shareholders might be concerned after seeing the share price drop 21% in the last quarter. But that doesn't undermine the rather lovely longer-term return, if you measure over the l...

  • These 5 Pot Stocks Lost at Least 15% in the First Quarter
    Motley Foollast month

    These 5 Pot Stocks Lost at Least 15% in the First Quarter

    The green rush went up in smoke for shareholders in these five marijuana stocks.

  • These Worst-Performing Pot Stocks Fell at Least 20% in March
    Motley Fool2 months ago

    These Worst-Performing Pot Stocks Fell at Least 20% in March

    There are some very familiar marijuana stocks among this bunch of losers.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of XXII earnings conference call or presentation 7-Mar-19 9:00pm GMT

    Full Year 2018 22nd Century Group Inc Earnings Call

  • The War on Tobacco, E-Cigs, and CBD May Be Coming to an End
    Motley Fool2 months ago

    The War on Tobacco, E-Cigs, and CBD May Be Coming to an End

    Food and Drug Administration Commissioner Scott Gottlieb's resignation has far-reaching implications.

  • 22nd Century Group (XXII) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    22nd Century Group (XXII) Q4 2018 Earnings Conference Call Transcript

    XXII earnings call for the period ending December 31, 2018.

  • How Does Investing In 22nd Century Group, Inc. (NYSEMKT:XXII) Impact The Volatility Of Your Portfolio?
    Simply Wall St.2 months ago

    How Does Investing In 22nd Century Group, Inc. (NYSEMKT:XXII) Impact The Volatility Of Your Portfolio?

    If you're interested in 22nd Century Group, Inc. (NYSEMKT:XXII), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stockRead More...

  • 3 Stocks Marijuana Investors Don't Need to Own
    Motley Fool3 months ago

    3 Stocks Marijuana Investors Don't Need to Own

    Even though some investors consider them to be marijuana stocks, they don't have the same potential as others.

  • InvestorPlace3 months ago

    Promise of Low Nicotine Fires Up 22nd Century Stock As Trading Scrutinized

    22nd Century Group (NYSE:XXII) is placing a bet that people will smoke tobacco (and maybe marijuana) even if it doesn't make them high. After a drop in mid January, XXII stock has regained some lost ground to be up 2.41% for the year so far.The company, which is based near Buffalo, NY, has a market cap of $317.2 million. It's on pace for revenue of $19 million when it reports 2018 results next week, up from $16.6 million in 2017 and $12.4 million in 2016. Losses are about equal to the revenue number.The company's technology creates very low nicotine tobacco which has been used in medical research, aimed at finding whether it can help people stop smoking.InvestorPlace - Stock Market News, Stock Advice & Trading TipsA home run for 22nd Century would be bringing such tobacco to market. It's seeking an FDA Premarket Tobacco Application (PMTA) for the purpose. It filed the application in December. * 10 Hot Stocks Leading the Market's Blitz Higher If you're buying 22nd Century stock, you're betting the approval comes through and that the company can sell the product, or at least that management can sell the company. Seeking Highs in the LowsCEO Henry Sicignano has been working this patch of business ground since 2010. At last report he owned 4.09% of 22nd Century, a stake worth $12.8 million. He was previously marketing director for a specialty tobacco company sold to R.J. Reynolds in 2002. In addition to researching low-nicotine tobacco, 22nd Century is researching low-THC marijuana. Because of its low market cap and share price, XXII stock is prone to wild swings based on hype. The spikes lead to short squeezes, then sudden falls in the stock price, and the inevitable flurry of charges of manipulation and resulting lawsuits.While the company is technically based in New York, most of its employees are in Mocksville, North Carolina, outside Winston-Salem, so its applications make news there.If the FDA approves the PMTA, 22nd Century would be allowed to mass produce its tobacco and offer it for sale, possibly as part of a smoking-cessation effort. If you believe the agency's nod is likely, it makes sense to buy the stock, because at a minimum 22nd Century could then become a buyout target for a large tobacco company, like Altria (NYSE:MO).That's the theory, anyway. Pump and Dump on XXII StockIn September, a short seller dubbed "Fuzzy Panda" wrote of suspected Securities and Exchange Commission (SEC) action involving 22nd Century. This may have involved phony articles from people working for Barry Honig, whom the SEC has called a "microcap fraudster" .Investigation reporting website Sharesleuth has accused promoters of operating a "stealth promotion network" on financial web sites. The promoters buy a block of shares, confederates write in praise of the company in question, the stock's price rises, then the shares are dumped.Shares in 22nd Century did indeed rise through 2017, the period where the articles are said to have come out. Shares peaked in January 2018 at almost $4 each. Since that peak they have mainly traded in a range of $2-$3 per share. They opened for trade on February 15 at $2.52. Bottom Line on 22nd Century StockA fool and his money were lucky to get together in the first place. Thus, I avoid low-valuation stocks that can be subject to manipulation. It is better to get rich slowly than to go broke all at once. * 9 U.S. Stocks That Are Coming to Life Again If an idea is good, venture capitalists or private equity people will lead the company forward to a public offering at a reasonable valuation, based on revenue and earnings.A company with reported revenue of $19 million does not deserve a market cap of $313 million. An exception may be made for a drug stock that is about to hear something great from regulators.I may be wrong, but I don't believe that to be the case here.Dana Blankenhorn is a financial and technology journalist. He is the author of a new mystery thriller, The Reluctant Detective Finds Her Family, available now at the Amazon Kindle store. Write him at danablankenhorn@gmail.com or follow him on Twitter at @danablankenhorn. As of this writing he owned no shares in companies mentioned in this article. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * Should You Buy, Sell, Or Hold These 7 Medical Cannabis Stocks? * 7 Strong Buy Stocks With Over 20% Upside * 7 Reasons Stock Buybacks Should Be Illegal Compare Brokers The post Promise of Low Nicotine Fires Up 22nd Century Stock As Trading Scrutinized appeared first on InvestorPlace.

  • The Only 2 Pot Stocks to Fall in January
    Motley Fool3 months ago

    The Only 2 Pot Stocks to Fall in January

    The most widely followed marijuana ETF ended up 48% last month, but 2 cannabis stocks went up in smoke.

  • Does 22nd Century Group, Inc.’s (NYSEMKT:XXII) CEO Pay Matter?
    Simply Wall St.5 months ago

    Does 22nd Century Group, Inc.’s (NYSEMKT:XXII) CEO Pay Matter?

    Henry Sicignano became the CEO of 22nd Century Group, Inc. (NYSEMKT:XXII) in 2015. First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will Read More...

  • Why 22nd Century Group Stock Bolted Higher in November
    Motley Fool5 months ago

    Why 22nd Century Group Stock Bolted Higher in November

    The FDA's efforts to lower cigarette consumption helped to boost 22nd Century Group's stock last month.

  • Performances of ETFs Investing in Cannabis Stocks in Week 48
    Market Realist5 months ago

    Performances of ETFs Investing in Cannabis Stocks in Week 48

    Cannabis industry ETFs are designed for those investors who don’t have the capacity to hold many stocks but are interested in diversifying within the cannabis sector.

  • Curaleaf Surpasses Revenue Estimates for Q3
    Market Realist6 months ago

    Curaleaf Surpasses Revenue Estimates for Q3

    Curaleaf Holdings (LDVTF) is one of the leading cannabis operators in the United States. Curaleaf surpassed Wall Street analysts’ estimate for revenue in the quarter, reporting revenue of $21.8 million compared to the expectation of $21.2 million (or 28.1 million Canadian dollars). Curaleaf Holdings reported a 289% increase in its revenue to $21.4 million in the third quarter compared to $5.5 million in the third quarter of 2017.

  • What to Expect from Curaleaf’s Q3 Earnings
    Market Realist6 months ago

    What to Expect from Curaleaf’s Q3 Earnings

    Curaleaf Holdings (LDVTF) is one of the leading cannabis companies in the United States. Curaleaf Holdings is set to release its Q3 2018 earnings today at 4:30 PM EST. In this article, we’ll look at Wall Street analyst expectations for Curaleaf’s Q3 earnings.

  • Why Was MedMen’s Trading Halted?
    Market Realist6 months ago

    Why Was MedMen’s Trading Halted?

    MedMen Enterprises (MMNFF) is a cannabis company focused on the cultivation, manufacturing, and marketing of cannabis. The chart above shows the stock price movements of MedMen to date in November. MedMen stock has fallen ~29.6% in November.

  • Why 22nd Century Group Stock Is Up Less Than 2% So Far in 2018
    Motley Fool6 months ago

    Why 22nd Century Group Stock Is Up Less Than 2% So Far in 2018

    A potential monopoly on tobacco supply isn't enough to stand on in a declining industry.

  • Thomson Reuters StreetEvents6 months ago

    Edited Transcript of XXII earnings conference call or presentation 8-Nov-18 9:00pm GMT

    Q3 2018 22nd Century Group Inc Earnings Call

  • Analyzing 22nd Century Group’s Year-to-Date Performance
    Market Realist6 months ago

    Analyzing 22nd Century Group’s Year-to-Date Performance

    22nd Century Group (XXII) is a plant biotechnology company that’s focused on developing technologies to manage the nicotine content in tobacco plants and the cannabinoids in cannabis plants using gene editing and plant breeding technologies.